Trial reportFrontiers in pharmacology2026
Efficacy of erector spinae plane block with liposomal bupivacaine for postoperative analgesia in patients undergoing open spinal surgery: a randomized controlled trial.
Trial report in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liposomal bupivacaine (LB) provides prolonged postoperative analgesia. This study aimed to evaluate the analgesic efficacy of erector spinae plane block (ESPB) using LB in patients undergoing spinal surgery. Methods: A total of 64 patients undergoing elective spinal surgery were randomly assigned in a 1:1 ratio to receive ESPB with 0.44% liposomal bupivacaine (LB group) or 0.4% ropivacaine (RH group) for postoperative pain management. The primary outcome was the incidence of rescue analgesia on the first postoperative day. Secondary outcomes included the incidence of rescue analgesia on the second and third postoperative days, visual analog scale (VAS) scores at various postoperative time points; time to first use of rescue analgesic; the cumulative area under the curve (AUC) of VAS scores, the Riker Sedation-Agitation Scale (RSAS) score at tracheal extubation; Quality of Recovery-15 (QoR-15) scores; opioid consumption; patient satisfaction and adverse events. Results: The RH group demonstrated a significantly higher incidence of rescue analgesic use than the LB group on postoperative days 1, 2, and 3 (37.5% vs. 9.4%, 59.4% vs. 18.8%, and 65.6% vs. 28.1%, respectively; all Conclusion: ESPB with LB provides prolonged postoperative analgesia, reduces opioid consumption, and enhances recovery quality following spinal surgery. These findings support the incorporation of LB as a valuable component of multimodal analgesia protocols for spinal procedures. Clinical Trial Registration: https://www.chictr.org.cn/showproj.html?proj=265855, identifier ChiCTR2500100055.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.